Meeting
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
Authors
Fengying Wu
Shanghai Pulmonary Hospital, Shanghai, China
Fengying Wu , Fei Zhou , Fuyou Zhao , Wei Zhang , Lei Wang , Jia Yu , Anweng Xiong , Jing Zhao , Wei Li , Guanghui Gao , Yayi He , Bing Bo , Shuyan Meng , Baohui Han , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
CTR20190681
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9131)
DOI
10.1200/JCO.2023.41.16_suppl.9131
Abstract #
9131
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
First Author: Pingli Wang
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura
Poster
2022 ASCO Annual Meeting
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
First Author: Jonathan W. Goldman
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao